In 2020, Sonosemi Medical Co., Ltd. was born in Shenzhen, the capital of scientific and technological innovation in China. Adhering to the business logic of integrating research, production and marketing and the open industrial synergy strategy, Sonosemi Medical carries out technological innovation around the clinical needs of coronary artery disease, peripheral vascular disease, structural heart disease and arrhythmia disease, aiming to provide a series of precise and intelligent product solutions and being committed to becoming a world-leading innovative enterprise of pan-vascular interventional diagnosis and treatment solutions.
Sonosemi Medical currently has first approved domestic Coronary Intravascular Lithotripsy System and the first domestic Intracardiac Echocardiography (ICE) system approved after it entered NMPA innovative medical device green channel in China. Additionally, the lithotripsy system for peripheral artery and Intravascular ultrasound system will be listed soon. Meanwhile, several innovative products are in research development, all of which will initially construct pan-vascular interventional diagnosis and treatment solutions.
Sonosemi Medical has gathered scientific research elites and operating talents with senior medical device industry background, and cooperates with domestic and overseas strength partners to promote innovative research and commercialization of domestic high-end medical devices, creating value for doctors and patients, and being enablers of smart medicine.